Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients

Cyclin-Dependent Kinase Modulators and Cancer Therapy

(2013) Marialucia Gallorini et al.   BIODRUGS

How I treat patients with relapsed chronic lymphocytic leukaemia

(2013) Kirsty Cuthill et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

(2013) S. Lim et al.   DEVELOPMENT

Rituximab in the treatment of non-Hodgkin's lymphoma – a critical evaluation of randomized controlled trials

(2013) Morag Meriel Griffin et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

(2013) Prithviraj Bose et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cyclin-dependent Kinase 9 Links RNA Polymerase II Transcription to Processing of Ribosomal RNA

(2013) Kaspar Burger et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

(2013) John J Nemunaitis et al.   Journal of Translational Medicine

Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial

(2013) A Cortelezzi et al.   LEUKEMIA

Emerging drug profile: cyclin-dependent kinase inhibitors

(2013) James S. Blachly et al.   LEUKEMIA & LYMPHOMA

The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling

(2013) Brijal M. Desai et al.   PLoS One

Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor

(2013) W Fu et al.   Cell Death & Disease

Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease

(2013) Ana E. Rodríguez-Vicente et al.   Cancer Genetics

Cyclin dependent kinases in cancer

(2012) Miriam Canavese et al.   CANCER BIOLOGY & THERAPY

Rituximab for chronic lymphocytic leukemia

(2012) Tadeusz Robak   EXPERT OPINION ON BIOLOGICAL THERAPY

Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

(2012) Xavier C. Badoux et al.   JOURNAL OF CLINICAL ONCOLOGY

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

(2011) X. C. Badoux et al.   BLOOD

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

(2011) Georg Feldmann et al.   CANCER BIOLOGY & THERAPY

Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma

(2011) Christopher Abdullah et al.   CELL CYCLE

The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature

(2011) Stéphane Lepretre et al.   LEUKEMIA & LYMPHOMA

The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells

(2011) W. Fu et al.   MOLECULAR CANCER THERAPEUTICS

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD